Respiratory Infection Model Development Services
Respiratory infections caused by bacteria, viruses, fungi, and emerging pathogens remain a major global health challenge, driving the urgent need for effective therapeutics. Successful translation of novel antimicrobials, antivirals, and immunomodulators depends on the availability of robust, well-characterized preclinical models that recapitulate human disease.
At Ace Therapeutics, we specialize in designing and developing custom respiratory infection models tailored to your specific research questions. Leveraging our deep expertise in respiratory disease and infectious disease biology, we provide flexible, high-quality CRO services that support every stage of your preclinical pipeline—from model establishment to comprehensive pharmacological assessment.
We work closely with clients to create infection models that match their desired pathogen, host background, disease course, and endpoint requirements. Our services encompass:
All studies are performed by experienced scientists using standardized operating procedures to ensure reproducibility and data integrity.
The table below summarizes our core model capabilities. We specialize in customizing these models—including the use of clinical isolates, antibiotic‑resistant strains, immunocompromised hosts, and alternative animal species—to address your unique research needs.
| Model Category | Infection Route | Key Readouts & Applications |
| Bacterial Pneumonia | Intratracheal, intranasal, oropharyngeal | Bacterial load (CFU) in lung/blood, survival, histopathology, cytokine profiling, BALF analysis, PK/PD of antibiotics |
| Viral Respiratory Infection | Intranasal, aerosol | Viral titer (plaque assay/TCID50), lung weight, histopathology, immune cell phenotyping, cytokine storm assessment, antiviral efficacy |
| Mycobacterial Infection | Aerosol, intratracheal | Mycobacterial load (CFU) in lungs/spleen, granuloma formation, histopathology (acid-fast stain), cytokine responses, long-term survival |
| Fungal Respiratory Infection | Intranasal, oropharyngeal aspiration | Fungal burden (CFU or GMS staining), lung histopathology, inflammatory markers, efficacy of antifungal agents |
| Polymicrobial & Chronic Infection | Intratracheal with agar beads | Biofilm quantification, chronic inflammation, tissue remodeling, long-term antibiotic efficacy |
Additional species (e.g., cotton rats, tree shrews) and infection routes (e.g., whole‑body aerosol) are available upon request.
We recognize that every drug development program has unique requirements. Our flexible approach allows us to design models with specific features:
To maximize the value of each infection model, we offer a comprehensive suite of downstream analyses that can be integrated into your study design:
Microbiological evaluation
Immunological profiling
Histopathology & immunohistochemistry
Bronchoalveolar lavage fluid (BALF) analysis
Pharmacokinetic & pharmacodynamic (PK/PD) integration
Biomarker analysis
Partner with Ace Therapeutics to obtain reliable, custom‑built respiratory infection models that drive your preclinical programs forward. Contact our team today to discuss your project requirements and learn how our tailored CRO services can support your drug development goals.
What types of respiratory pathogens can you develop models for?
We offer models for a wide spectrum of pathogens, including Gram‑positive/negative bacteria, respiratory viruses, mycobacteria, and fungi.
Do you offer models with specific animal strains or genetic modifications?
Yes. We routinely use standard inbred strains (BALB/c, C57BL/6) as well as outbred stocks. In addition, we can implement models in immunodeficient (nude, SCID, NSG), genetically modified (e.g., CFTR‑knockout, humanized ACE2), or age‑matched animals. Feasibility should be discussed during project planning.
How do you ensure the reproducibility of infection models?
Reproducibility is central to our service. We strictly control pathogen inoculum preparation (CFU/titer verification), animal characteristics (age, weight, sex), infection procedures, and environmental conditions. Each study includes appropriate control groups, and we provide detailed standard operating procedures so you can be confident in the consistency of the model.
Can you perform efficacy testing and PK/PD studies in the same model?
Absolutely. We frequently design integrated studies where pharmacokinetic sampling (plasma, lung tissue) is combined with efficacy endpoints (CFU reduction, survival) in the same animals. This approach minimizes animal use and provides a direct correlation between drug exposure and effect, facilitating PK/PD‑driven dose optimization.
What kind of data will I receive after study completion?
You will receive a comprehensive study report containing raw data (e.g., CFU counts, flow cytometry files, histology images), statistical analyses, detailed methodology, and an executive summary. Data are provided in common formats (Excel, PDF, PowerPoint) to support your internal decision‑making and regulatory submissions. Confidentiality and data ownership are fully protected.
Do you provide consultation on model selection before starting a study?
Yes, we strongly encourage an initial consultation to discuss your research goals, the mechanism of your test compound, and the most appropriate model design. Our scientists will provide expert guidance on pathogen strain, animal species, infection route, and endpoint selection to ensure the model answers your specific questions.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a preclinical research organization focused on respiratory diseases. We provide validated models and rigorous analysis services to support the development of novel therapeutics, from concept to preclinical insight.